Broader biotech positioning aligns with movements tracked across the nasdaq ecosystem.

Moderna's full pipeline may fuel long-term growth.

In the latest trading session, Moderna (MRNA) closed at $49.20, marking a -1.66% move from the previous day. The stock trailed the S&P 500, which registered a daily gain of 0.11%. On the other hand, ...

Moderna's shares have performed well this year, driven by clinical and regulatory progress. The company's results being reported on Friday won't be particularly strong, especially as its core market ...

Moderna helped to rapidly create vaccines for COVID-19, leading to a financial windfall. But those vaccine sales have waned, and so has the company's top line. There are opportunities ahead for ...

Moderna has faced good and bad times in recent years. Most recently, the FDA refused to review Moderna’s flu candidate -- then reversed course. Moderna (NASDAQ: MRNA) soared into the spotlight during ...

Moderna (NASDAQ:MRNA) has agreed to pay US$950 million to resolve a long-running patent dispute tied to the technology used in its COVID-19 vaccine. The pharmaceuticals giant announced it has reached ...

Moderna (MRNA) closed at $41.95 in the latest trading session, marking a +2.29% move from the prior day. The stock's change was more than the S&P 500's daily gain of 0.47%. Meanwhile, the Dow ...

The FDA refused last week to consider Moderna's application to sell a flu vaccine in 2026-2027. Today, the FDA changed its mind. The FDA had previously rejected Moderna's application, refusing even to ...

Looking back on biotechnology stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Incyte ...

Moderna (MRNA) came out with a quarterly loss of $2.11 per share versus the Zacks Consensus Estimate of a loss of $2.6. This compares to a loss of $2.5 per share a year ago. These figures are adjusted ...